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ABSTRACT 
A combined analysis of microcrystalline tests followed by LC-MS or GC-MS analysis is 
described. Microcrystalline tests are shown to be non-destructive as addition products formed 
were easily dissociated after the application of an appropriate solvent. Subsequent analysis of 
the sample was done to quantify the recovery of the drug. Examples were performed using 
the date rape drug γ-hydroxybutyrate (GHB) and the synthetic opioid methadone. 
 
INTRODUCTION 
Microcrystalline tests are chemical tests where microscopic crystals are formed upon the mix 
of a specifically chosen reagent together with a suspected drug sample. They provide a 
simple answer as to whether the suspected drug is present or not and can be carried out at 
very little cost. No specialist analytical instrumentation is required to perform a successful 
test; only a microscope is needed in order to observe the result. Result interpretation is based 
on direct crystal comparison with genuine drug standards which are carried out alongside [1]. 
 
Microcrystalline tests, as well as colour tests, are commonly used for presumptive testing of 
suspected drug samples [2]. Only a few grains of suspected drug are required for a positive 
result. However, microcrystalline tests can be more than just a simple screening technique. A 
recent publication suggests that microcrystalline tests can be used as a confirmation 
technique [3]. As microcrystals vary in appearance depending on the drug and the reagent, 
characteristics like crystal habit, colour and shape are specific enough to give confirmation of 
a result.  
 
Microcrystals formed between drugs of abuse and their corresponding reagents have been 
reported to be the result of addition reactions where drug and reagent form a complex [3]. The 
bond between drug and reagent molecules could be broken easily by adding solvent onto the 
crystals, dissolving the crystals and releasing the drug molecules back into solution. Solvents 
in which the analyte has optimum solubility are the most appropriate to chose.  
Following this theory, microcrystalline tests would be reversible and non-destructive in the 
sense that the analyte molecule can still be detected by other techniques even though the 
sample may be contaminated with reagents. The recycling of samples could be of use where 
seized samples have been insufficient to carry out confirmation tests. 
 
This study investigated a procedure to re-use microcrystalline tests for follow-up analysis by 
GC-MS or LC-MS. To demonstrate the effectiveness of the procedure two drugs of abuse, 
methadone and γ-hydroxybutyric acid (GHB), were chosen. Quantification was done using 
GC-MS and LC-MS to investigate the drug recovery. 
 
MATERIALS AND METHODS 
 Chemicals and materials 
γ-Hydroxybutyric acid sodium salt (99%) and methadone hydrochloride (> 98%) were 
purchased from Sigma-Aldrich (Gillingham, UK). GHB-d6 and methadone-d9 were purchased 
as ampoules (1 g/L in methanol) from Cerilliant (Round Rock, Texas, USA). Silver nitrate 
(99.9999%) was purchased from Sigma-Aldrich, lanthanum nitrate (> 99%) from Fluka 
(Gillingham, UK) and mercuric chloride from BDH chemicals (Poole, UK). Methanol (HPLC-
grade) and formic acid (analytical reagent grade) were from Fisher Scientific (Loughborough, 
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UK). All microcrystalline tests were carried out on standard microscope glass slides 
purchased from Fisher Scientific.  
 
 Microcrystalline test 
The reagent for GHB is an aqueous solution of silver nitrate and lanthanum nitrate (10 g/L 
each). Methadone was developed with an aqueous solution of mercuric chloride (10 g/L). 
Microcrystalline tests were set up by mixing 10 µL of drug (10 g/L in water) with 10 µL of the 
corresponding reagent on a glass slide. Progress of the microcrystal development was 
observed with a Meji ML 5000 microscope (Axbridge, UK) at 100 x magnification. The tests 
were left to fully dry at ambient temperature (drying time 15 minutes to 1 hour). 
 
Sample recovery and preparation for instrumental analysis 
The fully developed test slides were clamped onto a stand at an angle of approximately 10° to 
the horizontal for easy collection of the liquid sample. The solvent for dissolving the 
microcrystals was deionised water for both methadone and GHB. A 1.4 mL screw-cap vial 
was placed underneath one corner of the glass slide in order to catch the solvent running off 
the slide. In aliquots of 200 µL deionised water was smoothly run down the slide to dissolve 
all solids. Dissolving was sometimes aided by a gentle scratching movement done with a 
plastic pipette tip. A total volume of 800–1000 µL of deionised water was applied. Visual 
inspection of the rinsed slides with a microscope at 100 x magnification showed no crystal or 
other solid residues. 
The collected sample solution was blown down to dryness under a stream of nitrogen at 40°C 
with a drying time of 60 to 90 minutes and reconstituted in water for GHB and methanol for 
methadone. Final concentrations assuming full recovery were 100 mg/L for GHB and 50 mg/L 
for methadone, respectively. The deuterated analogues GHB-d6 and methadone-d9 were 
added directly before analysis of the recovered microcrystalline test samples resulting in final 
concentrations of 100 mg/L for GHB-d6 and 50 mg/L for methadone-d9. 
 
 LC-MS conditions 
GHB calibration standards were prepared in an aqueous solution ranging from 0 to 200 mg/L. 
GHB-d6 was added as an internal standard just before injection resulting in a concentration of 
100 mg/L. 
Liquid chromatography was performed on an Agilent Technologies LC-MS system using a 
1200 Series binary pump and an 1100 Series autosampler; it was operated by ChemStation 
software from Agilent Technologies (2005). Separation was achieved on an Agilent 
Technologies C18 column (Zorbax ODS 250 mm x 4.6 mm and 5 µm pore size) at ambient 
temperature. The column was eluted isocratically with 0.05% formic acid: methanol (90:10) at 
0.5 mL/min using an adapted version of a previously reported method [4]. The injection 
volume was 1 µL. 
Mass spectrometry was performed on an Agilent Technologies 6310 Ion Trap operated by 
6300 Series TrapControl software from Bruker Daltonik (2008) in smart mode. Ionisation was 
achieved using Electrospray in positive ionisation mode (ESI+). The ESI nebulizer was 
operated at 35.0 psi, drying gas nitrogen was run at 12.0 L/min with a drying temperature of 
350 °C. The scan range was set to 50-2200 m/z with a target mass at 105 m/z for [M+1]. The 
target mass was changed accordingly when looking for GHB adducts. The compound stability 
was set to 10% due to the fragility of the GHB molecule and the trap drive level was operated 
at 50%. 
 
GC-MS conditions 
Methadone calibration standards were prepared in methanol ranging from 0 to 100 mg/L. 
Methadone-d9 was added as an internal standard just before injection resulting in a 
concentration of 50 mg/L. 
Gas chromatography was performed using a Perkin Elmer Clarus 500 Gas Chromatograph 
equipped with an autosampler and a capillary injector operated at 250°C in split mode (10:1). 
Using an adapted version of a previously reported method [5] separation was achieved on an 
Agilent Technologies DB-1MS column (30 m x 0.25 mm and 0.25 µm film thickness) starting 
at 150°C and increasing at 12°C/min to a final temperature of 300°C giving a total run time of 
12.5 min. The carrier gas was helium at 1 mL/min and the injection volume was 1 µL. 
Mass spectrometry was performed using a Perkin Elmer Clarus 500 Mass Spectrometer 
operated with Perkin Elmer TurboMass (2008) software. The transfer line temperature was 
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held at 250°C. Ionisation was achieved using an Electron Impact (EI) source at 200°C with 
electron energy of 70 eV. The multiplier was set to 480 V. After 2 minutes solvent delay the 
methadone and methadone-d9 peaks were observed in total ion count (TIC) mode. 
Quantification was achieved by selected ion monitoring using the ions 72 m/z and 78 m/z at a 
dwell time of 0.2 s and a 0.1 s inter channel delay for methadone and methadone-d9, 
respectively. 
 
RESULTS AND DISCUSSION 
The chosen microcrystalline and instrumental methods were selected because samples could 
be analysed underivatised which minimised sample loss, and saved preparation time and the 
cost for derivatisation reagents. 
 
Microcrystalline testing of the drug sample 
The microcrystalline test for GHB with silver nitrate and lanthanum nitrate as reagent showed 
previously reported GHB right angle crystals which were slowly nucleating from the periphery 
of the liquid drop towards the centre [6] [Figure 1A]. When the drop was almost dry, reagent 
crystals formed a coating layer upon all developed crystals. 
The test for methadone developed differently. Methadone with mercuric chloride as reagent 
formed characteristic rosettes of branching rods [7]. When reagent and drug were mixed an 
instantaneous formation of white particles occurred. After a few minutes the drug-reagent 
crystals started to grow consuming the particle cloud as they increased in size. Only reagent 
crystals could be seen at the drying solvent front as methadone crystals preferred nucleation 
within the drop [Figure 1B].  
All crystal test samples were left to dry completely to ensure maximum formation of drug-
reagent crystals and to stay consistent throughout all experiments. However, it is normally 
advised that tests are observed well before complete dryness is achieved to avoid false 
results due to reagent crystal formation in the later stages of the test. 
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Figure 1 
Microcrystals for A) GHB and silver-lanthanum nitrate reagent and B) methadone and mercuric chloride reagent 
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Recycling of the microcrystalline test material 
In order to break up the bond formed between drug and reagent and therefore re-dissolving 
the drug molecules, solvent had to be applied. Deionised water was chosen because the 
majority of microcrystalline tests are carried out using aqueous solutions. Moreover, the 
viscosity of water as well as its surface tension make it the perfect solvent for this recycling 
procedure. The hydrophilic surface of microcrystals welcomed the applied water and 
disintegration of most crystals happened almost instantaneously. Water was applied in small 
aliquots of 200 μL to control the flow of solvent running over the edge of the slide [Figure 2]. 
Some crystal material did not dissolve in this step and was consequently washed off the slide 
in the stream of applied water. A total applied volume of 1000 µL deionised water was found 
to be sufficient to transfer the microcrystalline test sample analytically into a screw cap vial. 
Once transferred the final recycling step was to mix the solution with a vortex mixer for 
approximately 30 seconds inside the vial in order to dissolve all crystal material. 
The recovered samples were blown dry under nitrogen at low temperature. It was necessary 
to achieve complete dryness in order to monitor the recovered quantities of drug correctly. 
Reconstitution solvents were chosen according to the instrumental analytical technique which 
was carried out subsequently on the samples. 
No deuterated internal standards were used to monitor the microcrystalline test recovery. 
GHB-d6 and methadone-d9 are only available as solutions in methanol. Organic solvents like 
methanol have been found by the authors to interfere with the microcrystalline test. 
A sample clean-up in order to remove the reagents prior to the instrumental analysis was not 
done and so reagents remained within the solutions throughout the analysis. Although 
interferences could not be detected, a simple precipitation step may be done to remove the 
metal cations by adding sodium iodide to form the insoluble complexes of silver iodide and 
mercury iodide which could then be easily filtered off. 
 
 
Figure 2 
Schematic view of slide rinsing procedure for recycling of microcrystalline tests 
 
Instrumental analysis of the recovered sample 
Confirmation of the drug present was done via comparison of retention times and 
identification of characteristic ions in mass spectra obtained with standards. The retention 
times were 8.5 minutes for GHB and 7.9 minutes for methadone. Furthermore, mass 
spectrometry was used to quantify the drug recovery. Specific masses were monitored for the 
calibration and recovery study as pure drug standards were used throughout the experiments 
[Table 1]. The masses were chosen according to their high abundance in the standard mass 
spectra to give best sensitivity.  
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Table 1 
Retention times and selected ions used for quantification of the microcrystalline test recovery 
Compound Retention time 
(min) 
Ion 
(m/z) 
GHB 8.5 87 
GHB-d6 8.3 93 
Methadone 8.0 72 
Methadone-d9 7.9 78 
 
LC-MS analysis of GHB 
The mass spectra for GHB and its deuterated internal standard showed the molecular ion 
[M+1], one fragment due to the loss of water and common ESI+ adducts [Table 2].  
The base peak was used for quantification as it was the most abundant GHB ion in the 
spectrum. The molecular ion [M+1] was part of the background noise even at lowest 
ionisation settings in the ion trap presumably because the analyte desolvation before the trap 
was operated at 350°C. GHB was proven to be a thermally unstable molecule which 
dehydrates into a lactone [8]. The same behaviour was observed with the reconstituted 
microcrystalline samples which indicated that the bond formed between two GHB molecules 
and one silver ion (Ag+) to form the right angle GHB crystal was broken [9]. No silver or 
lanthanum adduct could be detected at concentrations analysed. 
Calibration linearity was achieved between 0 and 200 mg/L with a correlation coefficient of 
0.993 [Figure 3A]. The sample recovery was calculated to be 103 % (n = 11 with CV% = 5 %). 
 
Table 2 
Typical ESI+ ions for GHB and GHB-d6  
Ions  GHB  
(m/z) 
GHB-d6 
(m/z) 
Molecular ion [M+1] 105 111 
Base peak 87 93 
Na adduct 127 133 
K adduct 143 149 
 
GC-MS analysis of methadone 
The mass spectra for methadone and its deuterated internal standard showed low abundance 
of the molecular ion but a high abundance for the m/z of 72 and m/z of 78 fragments, 
respectively [Table 3]. The ion of 165 m/z was common for both compounds and therefore not 
used for quantification. 
 
Table 3 
Typical EI ionisation ions for methadone and methadone-d9  
Ions Methadone  
(m/z) 
Methadone-d9  
(m/z) 
Molecular ion 294 303 
Base peak 72 78 
 
The 72 m/z fragment was used for quantification even though on its own it is not sufficiently 
characteristic for methadone due to its small size. However, in conjunction with the 
beforehand performed microcrystalline test, the comparison of retention times and analysis of 
the TIC mass spectrum a definite identification was achieved.  
Calibration linearity was achieved between 0 and 100 mg/L with a correlation coefficient of 
0.999  [Figure 3B]. The sample recovery was calculated to be 105 % (n = 9 with CV% = 11%). 
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Figure 3 
Calibration for A) GHB via LC-MS and B) methadone via GC-MS 
Note: Peak area ratio (PA) of analyte divided by internal standard; n = 3; standard deviation as error bars 
 
Result evaluation 
The reagents themselves did not interfere with the GC or LC-MS results as only a few drug 
specific mass-to-charge ratios were evaluated in data treatment. Other detection techniques 
such as UV detection were not found suitable as the microcrystalline reagents interfered by 
absorbing in the UV. 
 
It has been demonstrated in this study that the ionic bond formed during the process of 
crystallisation could be easily broken by applying the appropriate solvent onto the 
microcrystalline test sample. The proposed procedure used 0.1 mg of the solid drug sample 
and delivered presumptive testing, screening, confirmation and quantification. Depending on 
the sensitivity of the microcrystalline test applied and the purity of the tested sample, even a 
lower concentration of the drug sample can be used. 
 
CONCLUSIONS 
Methadone and γ-hydroxybutyrate were successfully recovered after performing 
microcrystalline tests. It was proven that microcrystalline tests are reversible and non-
destructive. It was possible to use the microcrystalline test technique in conjunction with 
separation techniques to perform a successful qualitative and quantitative forensic drug 
analysis. Paired up both techniques can deliver a fast and reliable result using only a few 
micrograms of a suspected drug sample. 
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